Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1 (programmed death-ligand 1) expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.1
PD-L1 acts to switch off immune cells that would otherwise attack the cancer cells. By attaching to PD-L1 and reducing its effects, Tecentriq increases the ability of the immune system to attack the cancer cells and thereby slow down progression of the disease.2
In Bangladesh Tecentriq is approved for the following indications.3
- Tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC):
- after prior chemotherapy, or
- who are considered cisplatin ineligible and whose tumours have a PD-L1 expression ≥ 5%, or
- who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression.
- Tecentriq is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer NSCLC after prior chemotherapy.
For more disease and medicine related queries you may discuss with your physician.
In Bangladesh Tecentriq is available as
Single-use vial of 60 mg/ml (20 mL vial containing a total of 1,200 mg atezolizumab)
1. Roche - Tecentriq (atezolizumab) [Internet; cited 2020, March 17]. Retrieved from https://www.roche.com/products/product-details.htm?productId=8c738504-101a-40b9-867b-d907c578df51
2. Tecentriq | European Medicines Agency [Internet; cited 2020, March 17]. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq
3. Tecentriq Product Information _ FE-English RO 554-1267 _ March 2019